Advances in the management of chronic obstructive pulmonary disease

Bibliography

• PAUWELS RA, BUIST AS, CALVERLEY PM et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. I Respir. Grit. Care Med. (2001) 163(5):1256–1276.
   PubMedGoogle Scholar
• ••A comprehensive workshop summary onCOPD addressing current knowledge and future directions.
   Google Scholar
• VESTBO J, PRESCOTT E, LANGE P: Association of chronic mucus hypersecretion with FEVI decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. I Respir. Crit. Care Med. (1996) 153(5):1530–1535.
   PubMed Web of Science ®Google Scholar
• BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax (1997) 52\(Suppl. 5)S1–S28.
   Google Scholar
• Centers for Disease Control and Prevention. Current estimates from the National Health Interview Survey, 1995. Vital and health statistics. (1996)
   Google Scholar
• MURRAY CJ, LOPEZ AD: The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 (1996).
   Google Scholar
• LOPEZ AD, MURRAY CC: The global burden of disease, 1990-2020. Nat. Med. (1998) 4(11):1241–1243.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Report of final mortality statistics, 1979-1997 (1997).
   Google Scholar
• EVANS MD, PRYOR WA: Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. Am. J. Physiol (1994) 266(6 Pt 1):L593–L611.
   Google Scholar
• DAYAL H, KHUDER S, SHARRAR R et al.: Passive smoking in obstructive respiratory disease in an industrialized urban population. Environ. Res. (1994) 65(2):161–171.
   PubMed Web of Science ®Google Scholar
• LEUENBERGER P, SCHWARTZ J, ACKERMANN-LIEBRICH U et al: Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study). Swiss Study on Air Pollution and Lung Diseases in Adults, SAPALDIA Team. Am. J. Respir. Grit. Care Med. (1994) 150(5 Pt 1):1222–1228.
   Google Scholar
• •This study examined the association between passive exposure to tobacco smoke and respiratory symptoms in 4197 never-smoking adults. The association of passive smoking exposure with dyspnoea, wheeze, and asthma showed evidence of a dose-dependent increase with exposure (h/day), whereas association with symptoms of bronchitis was stronger with years of exposure.
   Google Scholar
• DENNIS RJ, MALDONADO D, NORMAN S et al.: Woodsmoke exposure and risk for obstructive airways disease among women. Chest (1996) 109(1):115–119.
   PubMed Web of Science ®Google Scholar
• HENDRICK DJ: Occupational and chronic obstructive pulmonary disease (COPD). Thorax (1996) 51(9):947–955.
   PubMed Web of Science ®Google Scholar
• •A review of current knowledge and controversies of occupational exposures in COPD.
   Google Scholar
• MAHADEVA R, LOMAS DA: Genetics and respiratory disease. 2. al-antitrypsin deficiency, cirrhosis and emphysema. Thorax (1998) 53(6):501–505.
   Google Scholar
• HUANG SL, SUCH, CHANG SC: Tumor necrosis factor-a gene polymorphism in chronic bronchitis. Am. I Respir. Crit. Care Med. (1997) 156(5):1436–1439.
   PubMed Web of Science ®Google Scholar
• SMITH CA, HARRISON DJ: Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet (1997) 350(9078):630–633.
   PubMed Web of Science ®Google Scholar
• FINKELSTEIN R, FRASER RS, GHEZZO H et al.: Alveolar inflammation and its relation to emphysema in smokers. Am. J. Respir. Grit. Care Med. (1995) 152(5 Pt 1):1666–1672.
   Google Scholar
• O'SHAUGHNESSY TC, ANSARI TW, BARNES NC et al: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8' T lymphocytes with FEVI. Am. I Respir. Crit. Care Med. (1997) 155(3):852–857.
   PubMed Web of Science ®Google Scholar
• PESCI A, BALBI B, MAJORI M et al: Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Respic (1998) 12(2):380–386.
   PubMed Web of Science ®Google Scholar
• KEATINGS VM, COLLINS PD, SCOTT DM et al.: Differences in interleukin-8 and tumor necrosis factor-a in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. I Respir. Crit. Care Med. (1996) 153(2):530–534.
   PubMed Web of Science ®Google Scholar
• DI STEFANO A, CAPELLI A, LUSUARDI M et al.: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. Respir. Crit. Care Med. (1998) 158(4):1277–1285.
   PubMed Web of Science ®Google Scholar
• MAJORI M, CORRADI M, CAMINATI A et al: Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. Allergy Clin. Immunol (1999) 103(3 Pt 1):458–462.
   Google Scholar
• HILL AT, BAYLEY D, STOCKLEY RA: The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am. Respir. Crit. Care Med. (1999) 160(3):893–898.
   PubMed Web of Science ®Google Scholar
• REPINE JE, BAST A, LANKHORST I: Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am. I Respir. Grit. Care Med. (1997) 156(2 Pt 1):341–357.
   Google Scholar
• PRATICO D, BASILI S, VIERI M et al: Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2a-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. (1998) 158(6):1709–1714.
   PubMed Web of Science ®Google Scholar
• DEKHUIJZEN PN, ABEN K, DEKKER I et al.: Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. .1 Respir. Grit. Care Med. (1996) 154(3 Pt 1):813–816.
   Google Scholar
• BARNES PJ, KARIN M: Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl. Med. (1997) 336(15):1066–1071.
   PubMed Web of Science ®Google Scholar
• STOCKLEY RA: Neutrophils and protease/antiprotease imbalance. Am.Respic Crit. Care Med. (1999)160(5 Pt 2):S49–S52.
   Google Scholar
• GOTTLIEB DJ, STONE PJ, SPARROW D et al: Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am. I Respir. Crit. Care Med. (1996) 154(5):1290–1295.
   PubMed Web of Science ®Google Scholar
• REID PT, MARSDEN ME, CUNNINGHAM GA et al: Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in Type II alveolar epithelial cells. FEBS Lett. (1999) 457(1):33–37.
   PubMed Web of Science ®Google Scholar
• CULPITT SV, MAZIAK W, LOUKIDIS S et al.: Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. I Respic Crit. Care Med. (1999) 160(5 Pt 1):1635–1639.
   Google Scholar
• FINLAY GA, O'DRISCOLL LR, RUSSELL KJ et al.: Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. I Respic Crit. Care Med. (1997) 156(1):240–247.
   Google Scholar
• •This study highlights the role of MIVIPs in emphysema.
   Google Scholar
• OHNISHI K, TAKAGI M, KUROKAWA Yet al.: Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab. Invest. (1998) 78(9):1077–1087.
   Google Scholar
• HAUTAMAKI RD, KOBAYASHI DK, SENIOR RM et al.: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 277(5334):2002–2004.
   PubMed Web of Science ®Google Scholar
• O'DONNELL DE, REVILL SM, WEBB KA: Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am. I Respic Crit. Care Med. (2001) 164(5):770–777.
   PubMed Web of Science ®Google Scholar
• O'DONNELL DE, LAM M, VVEBB KA: Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. I Respic Crit. Care Med. (1998) 158(5 Pt 1):1557–1565.
   Google Scholar
• HAY JG, STONE P, CARTER J et al: Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur. Respic (1992) 5(6):659–664.
   PubMed Web of Science ®Google Scholar
• VATHENEN AS, BRITTON JR, EBDEN P et al.: High-dose inhaled albuterol in severe chronic airflow limitation. Am. Rev Resp. Dis. (1988) 138(4):850–855.
   PubMedGoogle Scholar
• HIGGINS BG, POWELL RM, COOPERS et al: Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Ear: Respic (1991) 4(4):415–420.
   PubMed Web of Science ®Google Scholar
• CHRYSTYN H, MULLEY BA, PEAKE MD: Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMI (1988) 297(6662):1506–1510.
   PubMed Web of Science ®Google Scholar
• WRIGHT J, BROCKLEBANK D, RAM F: Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD). Qual Sal Health Care (2002) 11(4):376–382.
   PubMedGoogle Scholar
• BARNES PJ: Muscarinic receptor subtypes in airways. Ear. Respic J. (1993) 6(3):328–331.
   PubMed Web of Science ®Google Scholar
• BEEH KM, WELTE T, BUHL R: Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration (2002) 69(4):372–379.
   PubMed Web of Science ®Google Scholar
• LIESKER J, WIJKSTRA PJ, TEN HACKEN NH et al: A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest (2002) 121(2):597–608.
   PubMed Web of Science ®Google Scholar
• •A comprehensive literature review of the beneficial effects of bronchodilators on exercise capacity in COPD.
   Google Scholar
• MARTIN RJ, BARTELSON BL, SMITH P et al.: Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest (1999) 115(5):1338–1345.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: The pharmacological properties of tiotropium. Chest (2000) 117\(Suppl. 2):635–665.
   Google Scholar
• LITTNER MR, ILOWITE JS, TASHKIN DP et al.: Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. I Respir: Crit. Care Med. (2000) 161(4 Pt 1):1136–1142.
   Google Scholar
• VAN NOORD JA, BANTJE TA, ELAND ME et al.: A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax (2000) 55(4):289–294.
   Google Scholar
• •This prospective multi-centre trial demonstrates the effectiveness of tiotropium in maintaining bronchodilation with once-daily dosing.
   Google Scholar
• CASABURI R, BRIGGS D Jr, DONOHUE JF et al.: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest (2000) 118(5):1294–1302.
   Google Scholar
• VINCKEN W, VAN NOORD JA, GREEFHORST AP et al.: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. (2002) 19(2):209–216.
   PubMed Web of Science ®Google Scholar
• CASABURI R, MAHLER DA, JONES PW et al.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Ear. Respic (2002) 19(2):217–224.
   PubMed Web of Science ®Google Scholar
• DONOHUE JF, VAN NOORD JA, BATEMAN ED et al.: A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest (2002) 122(1):47–55.
   PubMed Web of Science ®Google Scholar
• BACH P: Effects of beta agonists on airway effector cells. In: Beta2-agonists M asthma treatment. Pauwels R, O'Byrne PM (Eds), Barnes & Noble, USA (1997):35–36.
   Google Scholar
• SESTINI P, RENZONI E, ROBINSON S et al.: Short-acting 132 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2002) 4:CD001495.
   Google Scholar
• SHIM CS, WILLIAMS MH, JR: Bronchodilator response to oral aminophylline and terbutaline versus aerosol albuterol in patients with chronic obstructive pulmonary disease. Am. Med. (1983) 75(4):697–701.
   PubMed Web of Science ®Google Scholar
• ULRIK CS: Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax (1995) 50(7):750–754.
   PubMed Web of Science ®Google Scholar
• BOYD G, MORICE AH, POUNSFORD JC et al.: An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Ear: Respic J. (1997) 10(4):815–821.
   PubMed Web of Science ®Google Scholar
• LOTVALL J: Pharmacological similarities and differences between 32-agonists. Respic Med. (2001) 95(Suppl. B)57–S11.
   Google Scholar
• RENNARD SI, ANDERSON W, ZUWALLACK R et al: Use of a long-acting inhaled 32-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. I Respic Crit. Care Med. (2001) 163(5):1087–1092.
   PubMed Web of Science ®Google Scholar
• MAHLER DA, DONOHUE JF, BARBEE RA et al.: Efficacy of salmeterol xinafoate in the treatment of COPD. Chest (1999) 115(4):957–965.
   PubMed Web of Science ®Google Scholar
• APPLETON S, POOLE P, SMITH B et al.: Long-acting I32-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst. Rev. (2002) 3:CD001104.
   Google Scholar
• AYERS ML, MEJIA R, WARD J et al: Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Ear: Respir: J. (2001) 17(6):1132–1137.
   PubMed Web of Science ®Google Scholar
• PATAKAS D, ANDREADIS D, MAVROFRIDIS E et al.: Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir. Med. (1998) 92(9):1116–1121.
   PubMed Web of Science ®Google Scholar
• WEINER P, MAGADLE R, BERAR-YANAY N et al.: The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD. Chest (2000) 118(3):672–678.
   PubMed Web of Science ®Google Scholar
• JOHNSON M, RENNARD S: Alternative mechanisms for long-acting 32-adrenergic agonists in COPD. Chest (2001) 120(1):258–270.
   PubMed Web of Science ®Google Scholar
• BENHAMOU D, CUVELIER A, MUIR JF et al.: Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir. Med. (2001) 95(10):817–821.
   PubMed Web of Science ®Google Scholar
• AALBERS R, AYRES J, BACKER V et al.: Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur: Respir: J. (2002) 19(5):936–943.
   PubMed Web of Science ®Google Scholar
• •A large trial demonstrating dose-effectiveness of formoterol on bronchodilation in COPD patients.
   Google Scholar
• CAZZOLA M, CENTANNI S, REGORDA C et al: Onset of action of single doses of formoterol administered via turbuhaler in patients with stable COPD. Pulm. Pharmacol Ther: (2001) 14(1):41–45.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, D'AMATO M, CALIFANO C et al.: Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin. Thec (2002) 24(4):595–604.
   Google Scholar
• DAHL R, GREEFHORST LA, NOWAK D et al.: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. I Respir. Grit. Care Med. (2001) 164(5):778–784.
   PubMed Web of Science ®Google Scholar
• HOGAN TJ, GEDDES R, GONZALEZ ER: An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin. Titer. (2003) 25(1):285–297.
   Google Scholar
• WADBO M, LOFDAHL CG, LARSSON K et al.: Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur. Respic J. (2002) 20(5):1138–1146.
   PubMed Web of Science ®Google Scholar
• LIESKERJ, VAN DE VELDE V, MEYSMAN M et al.: Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir: Med. (2002) 96(8):559–566.
   Google Scholar
• ROSSI A, KRISTUFEK P, LEVINE BE et al.: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest (2002) 121(4):1058–1069.
   PubMed Web of Science ®Google Scholar
• KOTTAKIS J, CIOPPA GD, CREEMERS J et al: Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can. Respir. I (2002) 9(2):107–115.
   PubMedGoogle Scholar
• CELIK G, KAYACAN 0, BEDER S et al: Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration (1999) 66(5):434–439.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, SANTANGELO G, PICCOLO A et al: Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol (1994) 7(2):103–107.
   PubMedGoogle Scholar
• CAZZOLA M, MATERA MG, SANTANGELO G et al.: Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir: Med. (1995) 89(5):357–362.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, DI PERNA F, NOSCHESE P et al.: Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur. Respic J. (1998) 11(6):1337–1341.
   PubMed Web of Science ®Google Scholar
• AU DH, CURTIS JR, EVERY NR et al.: Association between inhaled 3-agonists and the risk of unstable angina and myocardial infarction. Chest (2002) 121(3):846–851.
   PubMed Web of Science ®Google Scholar
• YANG CT, LIN HC, LIN MC et al: Effect of 32-adrenoceptor agonists on plasma potassium and cardiopulmonary responses on exercise in patients with chronic obstructive pulmonary disease. Eur: Clin. Pharmacol (1996) 49(5):341–345.
   Web of Science ®Google Scholar
• EIDELMAN DH, SAMI MH, MCGREGOR M et al: Combination of theophylline and salbutamol for arrhythmias in severe COPD. Chest (1987) 91(6):808–812.
   PubMed Web of Science ®Google Scholar
• ROSSINEN J, PARTANEN J, STENIUS-AARNIALA B et al: Salbutamol inhalation has no effect on myocardial ischaemia, arrhythmias and heart-rate variability in patients with coronary artery disease plus asthma or chronic obstructive pulmonary disease. J. Intern. Med. (1998) 243(5):361–366.
   PubMed Web of Science ®Google Scholar
• SUISSA S, ASSIMES T, ERNST P: Inhaled short-acting 13 agonist use in COPD and the risk of acute myocardial infarction. Thorax (2003) 58(1):43–46.
   PubMed Web of Science ®Google Scholar
• SEIDER N, ABINADER EG, OLIVEN A: Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease. Chest (1993) 104(4):1070–1074.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, IMPERATORE F, SALZILLO A et al.: Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest (1998) 114(2):411–415.
   PubMed Web of Science ®Google Scholar
• •This study evaluated the safety of long-acting I3-agonists in COPD patients with pre-existing cardiac arrhythmias and hypoxaemia. It showed increased ventricular ectopy and a dose-dependent hypokalaemia.
   Google Scholar
• HOGG JC, MACKLEM PT, THURLBECK WM: Site and nature of airway obstruction in chronic obstructive lung disease. N Engl. J. Med. (1968) 278(25):1355–1360.
   PubMed Web of Science ®Google Scholar
• SIAFAKAS NM, VERMEIRE P, PRIDE NB et al.: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur. Respir. J. (1995) 8(8):1398–1420.
   PubMed Web of Science ®Google Scholar
• Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am. J. Respir. Crit. Care Med. (1995) 152(5 Pt 2):577–5121.
   Google Scholar
• CALLAHAN CM, DITTUS RS, KATZ BP: Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann. Intern. Med. (1991) 114(3):216–223.
   PubMed Web of Science ®Google Scholar
• WEIR DC, GOVE RI, ROBERTSON AS et al: Response to corticosteroids in chronic airflow obstruction: relationship to emphysema and airways collapse. Eur. Respic J. (1991) 4(10):1185–1190.
   PubMed Web of Science ®Google Scholar
• SENDEROVITZ T, VESTBO J, FRANDSEN J et al.: Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. Respir: Med. (1999) 93(10):715–718.
   PubMed Web of Science ®Google Scholar
• POSTMA DS, PETERS I, STEENHUIS EJ et al.: Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur. Respic J. (1988) 1(1):22–26.
   Google Scholar
• POSTMA DS, STEENHUIS EJ, VAN DER WEELE LT et al.: Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur. Respic Dis. (1985) 67(1):56–64.
   Google Scholar
• DECRAMER M, STAS KJ: Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am. Rev Respic Dis. (1992) 146(3):800–802.
   PubMedGoogle Scholar
• DECRAMER M, LACQUET LM, FAGARD R et al: Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am. I Respic Grit. Care Med. (1994) 150(1):11–16.
   PubMed Web of Science ®Google Scholar
• DECRAMER M, DE BOCK V, DOM R: Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am. I Respic Crit. Care Med. (1996) 153(6 Pt 1):1958–1964.
   Google Scholar
• WOOD-BAKER R, WALTERS E: Corticosteroids for treating acute exacerbation of chronic obstructive pulmonary disease. Cochrane Library (1998) 4th edn. (Oxford: update software, 1998).
   Google Scholar
• ALBERT RK, MARTIN TR, LEWIS SW: Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann. Intern. Med. (1980) 92(6):753–758.
   PubMed Web of Science ®Google Scholar
• DAVIES L, ANGUS RIVI, CALVERLEY PM: Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet (1999) 354(9177):456–460.
   PubMed Web of Science ®Google Scholar
• EMERMAN CL, CONNORS AF, LUKENS TW et al.: A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest (1989) 95(3):563–567.
   PubMed Web of Science ®Google Scholar
• THOMPSON WH, NIELSON CP, CARVALHO P et al.: Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am. I Respic Crit. Care Med. (1996) 154(2 Pt 1):407–412.
   Google Scholar
• NIEWOEHNER DE, ERBLAND ML, DEUPREE RH et al.: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl. I Med. (1999) 340(25):1941–1947.
   PubMed Web of Science ®Google Scholar
• ••This study provides the most convincing data on the effectiveness of systemic steroids in acute COPD exacerbation.
   Google Scholar
• SINGH JM, PALDA VA, STANBROOK MB et al.: Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch. Intern. Med. (2002)V 162(22):2527–2536.
   Google Scholar
• •this is a comprehensive review of existing literature on systemic corticosteroid therapy in acute exacerbation of COPD.
   Google Scholar
• SHORTALL SP, BLUM J, OLDENBURG FA et al.: Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen. Respic Care (2002) 47(2):154–158.
   PubMedGoogle Scholar
• NISHIMURA K, KOYAMA H, IKEDA A et al.: The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD. Chest (1999) 115(1):31–37.
   PubMed Web of Science ®Google Scholar
• PAGGIARO PL, DAHLE R, BAKRAN I et al.: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet (1998) 351(9105):773–780.
   PubMed Web of Science ®Google Scholar
• VAN GRUNSVEN PM, VAN SCHAYCK CP, DERENNE JP et al: Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax (1999) 54(1):7–14.
   PubMed Web of Science ®Google Scholar
• BURGE PS, CALVERLEY PM, JONES PW et al.: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMI(2000) 320(7245):1297–1303.
   PubMed Web of Science ®Google Scholar
• Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. Lung Health Study Research Group. N Engl. I Med. (2000) 343(26):1902–1909.
   PubMedGoogle Scholar
• VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 353(9167):1819–1823.
   PubMed Web of Science ®Google Scholar
• PAUWELS RA, LOFDAHL CG, LAMNEN LA et al.: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N EngL I Med. (1999) 340(25):1948–1953.
   Google Scholar
• ALSAEEDI A, SIN D, MCALISTER FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. I Med. (2002) 113(1):59–65.
   Google Scholar
• ••A systematic review of the role of inhaled corticosteroids in COPD.
   Google Scholar
• JONES PW WILLITS LR, BURGE PS et al.: Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur. Respic 1 (2003) 21(1):68–73.
   Google Scholar
• SIN DD, TU JV: Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am. I Respic Grit. Care Med. (2001) 164(4):580–584.
   PubMed Web of Science ®Google Scholar
• JARAD NA, VVEDZICHA JA, BURGE PS et al.: An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respic Med. (1999) 93(3):161–166.
   Google Scholar
• VAN DER VALK P, MONNINKHOF E, VAN DER PALEN J et al: Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. I Respic Grit. Care Med. (2002) 166(10):1358–1363.
   PubMed Web of Science ®Google Scholar
• JOHNELL 0, PAUWELS R, LOFDAHL CG et al.: Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide
   Google Scholar
• •• Turbuhaler. Ear: Respir. J. (2002) 19(6):1058–1063.
   Google Scholar
• In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest (1994) 105(5):1411–1419.
   Google Scholar
• Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBI VENT Inhalation Solution Study Group. Chest (1997) 112(6):1514–1521.
   PubMedGoogle Scholar
• CHRISCHILLES E, GILDEN D, KUBISIAK J et al.: Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am. Manag. Care (2002) 8(10):902–911.
   PubMed Web of Science ®Google Scholar
• VAN NOORD JA, DE MUNCK DR, BANTJE TA et al: Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Ear. Respir. 1 (2000) 15(5):878–885.
   Google Scholar
• ZUWALLACK RL, MAHLER DA, REILLY D et al: Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest (2001) 119(6):1661–1670.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, DI LORENZO G, DI PERNA F et al.: Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest (2000) 118(6):1576–1581.
   Google Scholar
• BARNES PJ: Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Ear: Respic J. (2002) 19(1):182–191.
   PubMed Web of Science ®Google Scholar
• •Review of clinical data and molecular mechanisms of potential beneficial effects from combination therapy.
   Google Scholar
• MAK JC, NISHIKAWA M, SHIRASAKI H et al: Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J. Clin. Invert. (1995) 96(1):99–106.
   PubMed Web of Science ®Google Scholar
• ADCOCK IM, MANEECHOTESUVVAN K, USMANI 0: Molecular interactions between glucocorticoids and long-acting beta2-agonists. I Allergy Clin. Immunol (2002) 110(6 Suppl.):S261–S268.
   Google Scholar
• MAHLER DA, WIRE P, HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive Pulmonary Disease. Am. J. Respir. Grit. Care Med. (2002) 166(8):1084–1091.
   PubMed Web of Science ®Google Scholar
• SZAFRANSKI W, CUKIER A, RAMIREZ A et al.: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respic J. (2003) 21(1):74–81.
   PubMed Web of Science ®Google Scholar
• CALVERLEY P, PAUWELS R, VESTBO J et al.: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 361(9356):449–456.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ: Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. (1998) 157(2):351–370.
   PubMed Web of Science ®Google Scholar
• VASSALLO R, LIPSKY JJ: Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. Mayo Clin. Proc. (1998) 73(4):346–354.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of the role of theophylline in COPD management.
   Google Scholar
• BARNES PJ: Chronic obstructive pulmonary disease. N Engl. I Med. (2000) 343(4):269–280.
   PubMed Web of Science ®Google Scholar
• •A concise review of the present knowledge of pathogenesis, therapeutic options and future directions in COPD.
   Google Scholar
• FERGUSON GT: Update on pharmacologic therapy for chronic obstructive pulmonary disease. Clin. Chest Med. (2000) 21(4):723–738.
   PubMed Web of Science ®Google Scholar
• CHITKARA RK, SARINAS PS: Recent advances in diagnosis and management of chronic bronchitis and emphysema. Carr. Opin. Pulm. Med. (2002) 8(2):126–136.
   PubMed Web of Science ®Google Scholar
• RAM FS, JONES PW, CASTRO AA et al: Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev (2002) 4:CD003902.
   Google Scholar
• GAUTHIER AP, YAN S, SLIWINSKI P et al.: Effects of fatigue, fiber length, and aminophylline on human diaphragm contractility. Am. J. Respir. Grit. Care Med. (1995) 152(1):204–210.
   PubMed Web of Science ®Google Scholar
• VAZ FRAGOSO CA, MILLER MA: Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. (1993) 147(6 Pt 2):540–547.
   Google Scholar
• Tobacco use-United States, 1900-1999. MMWR Morb. Mortal. Wkly Rep. (1999) 48(43):986–993.
   PubMedGoogle Scholar
• RIGOTTI NA: Clinical practice. Treatment of tobacco use and dependence. N Engl. J. Med. (2002) 346(7):506–512.
   PubMed Web of Science ®Google Scholar
• ••A timely review for practicing physicians on treatment of tobacco dependence.
   Google Scholar
• The health benefits of smoking cessation: a report of the Surgeon General (1990) (DHHS publication no. (CDC) 90–8416).
   Google Scholar
• A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA (2000) 283(24):3244–3254.
   Google Scholar
• HUGHES JR, GOLDSTEIN MG, HURT RD et al.: Recent advances in the pharmacotherapy of smoking. JAMA (1999) 281(1):72–76.
   PubMed Web of Science ®Google Scholar
• LANCASTER T, STEAD L, SILAGY C et al.: Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. EMI (2000) 321(7257):355–358.
   Google Scholar
• HAJEK P, WEST R, FOULDS J et al: Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch. Intern. Med. (1999) 159(17):2033–2038.
   PubMed Web of Science ®Google Scholar
• BOHADANA A, NILSSON F, RASMUSSEN T et al.: Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch. Intern. Med. (2000) 160(20):3128–3134.
   PubMed Web of Science ®Google Scholar
• Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of Transdermal Nicotine in Patients with Coronary artery disease. Arch. Intern. Med. (1994) 154(9):989–995.
   PubMedGoogle Scholar
• JOSEPH AM, NORMAN SM, FERRY LH et al.: The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl. J. Med. (1996) 335(24):1792–1798.
   PubMed Web of Science ®Google Scholar
• BENOWITZ NL, GOURLAY SG: Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. Am. Coll. Cardiol (1997) 29(7):1422–1431.
   PubMed Web of Science ®Google Scholar
• SACHS DP, BENOWITZ NL: Individualizing medical treatment for tobacco dependence. Eut: Respir. J. (1996) 9(4):629–631.
   PubMed Web of Science ®Google Scholar
• LILLINGTON GA, LEONARD CT, SACHS DP: Smoking cessation. Techniques and benefits. Clin. Chest Med. (2000) 21(1):199–208, xi.
   Google Scholar
• •This paper outlines a practical approach to smoking cessation.
   Google Scholar
• JORENBY DE, LEISCHOW SJ, NIDES MA et al.: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl. J. Med. (1999) 340(9):685–691.
   PubMed Web of Science ®Google Scholar
• HALL SM, REUS VI, MUNOZ RF et al: Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch. Gen. Psychiatry (1998) 55(8):683–690.
   PubMed Web of Science ®Google Scholar
• PROCHAZKA AV, WEAVER MJ, KELLER RT et al.: A randomized trial of nortriptyline for smoking cessation. Arch. Intern. Med. (1998) 158(18)2035–2039.
   Google Scholar
• ROSE JE, BEHM FM, VVESTMAN EC et al.: Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacy] Ther: (1994) 56(1):86–99.
   PubMed Web of Science ®Google Scholar
• ROSE JE, BEHM FM, VVESTMAN EC: Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacy] Biochem. Behav. (2001) 68(2):187–197.
   PubMed Web of Science ®Google Scholar
• BRAUER LH, BEHM FM, VVESTMAN EC et al.: Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology (Ben) (1999) 143(4):339–346.
   PubMed Web of Science ®Google Scholar
• ROSE JE, VVESTMAN EC, BEHM FM et al.: Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacy] Biochem. Behav. (1999) 62(1):165–172.
   PubMed Web of Science ®Google Scholar
• WATKINS S, EPPING-JORDAN MP, KOOB GF et al.: Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacy] Biochem. Behav. (1999) 62(4):743–751.
   PubMed Web of Science ®Google Scholar
• DRAZENJM: Leukotrienes as mediators of airway obstruction. Am. J. Respir. Crit. Care Med. (1998) 158(5 Pt 3):5193–5200.
   Google Scholar
• DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl. I Med. (1999) 340(3):197–206.
   PubMed Web of Science ®Google Scholar
• COLEMAN RA, EGLEN RM, JONES RL et al.: Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv. Prostaglandin Thromboxane Leukot. Res. (1995) 23:283–285.
   PubMedGoogle Scholar
• YOKOMIZO T, IZUMI T, CHANG K et al.: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature (1997) 387(6633):620–624.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, CENTANNI S, BOVERI B et al.: Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Respiration (2001) 68(5):452–459.
   PubMed Web of Science ®Google Scholar
• GOMPERTZ S, STOCKLEY RA: A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest (2002) 122(1):289–294.
   PubMed Web of Science ®Google Scholar
• LEE E, UNDO T, JACKSON N et al: Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am. Respir. Crit. Care Med. (1999) 160(6):2079–2085.
   PubMed Web of Science ®Google Scholar
• KILFEATHER S:5-lipoxygenase inhibitors for the treatment of COPD. Chest (2002) 121(5 Suppl.):197S–200S.
   Google Scholar
• •A review of present knowledge and future directions of leukotriene inhibitors in COPD.
   Google Scholar
• VERNOOY JH, KUCUKAYCAN M, JACOBS JA et al.: Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am. .1. Respir. Crit. Care Med. (2002) 166(9):1218–1224.
   Google Scholar
• DE BOER WI, SONT JK, VAN SCHADEWIJK A et al.: Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. Pathol (2000) 190(5):619–626.
   Google Scholar
• WHITE JR, LEE JM, YOUNG PR et al: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration." Biol. Chem. (1998) 273(17):10095–10098.
   Google Scholar
• YANG XD, CORVALAN JR, WANG P et al.: Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. J. Leukoc. Biol. (1999) 66(3):401–410.
   PubMed Web of Science ®Google Scholar
• DE BOER WI: Cytokines and therapy in COPD: a promising combination? Chest (2002) 121(5 Suppl.):209S–218S.
   Google Scholar
• JONES SA, DEWALD B, CLARK-LEWIS I et al: Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2. J. Biol. Chem. (1997) 272(26):16166–16169.
   Google Scholar
• PRETOLANI M: Interleukin-10: an anti-inflammatory cytokine with therapeutic potential. Clin. Exp. Allergy (1999) 29(9):1164–1171.
   PubMed Web of Science ®Google Scholar
• TAKANASHI S, HASEGAWA Y, KANEHIRA YInterleuldn-10 level insputum is reduced in bronchial asthma, COPD and in smokers. Eur. Respir: I (1999) 14(2):309–314.
   PubMed Web of Science ®Google Scholar
• MASCALI J, CVIETUSA P, NEGRI J et al.: Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann. Allergy Asthma Immunol (1996) 77(1):34–38.
   PubMed Web of Science ®Google Scholar
• PITSIOU G, KYRIAZIS G, HATZIZISI 0 et al.: Tumor necrosis factor-alpha serum levels, weight loss and tissue oxygenation in chronic obstructive pulmonary disease. Respir. Med. (2002) 96(8):594–598.
   Google Scholar
• WOUTERS EF, CREUTZBERG EC, SCHOLS AM: Systemic effects in COPD. Chest (2002) 121(5 Suppl.):127S–130S.
   Google Scholar
• •A discussion of the role of cytokines and their constitutional effects in COPD.
   Google Scholar
• SCHMITZ H, FROMM M, BENTZEL CJ et al.: Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. j. Cell Sci. (1999) 112(Pt 1):137–146.
   PubMed Web of Science ®Google Scholar
• KAMPF C, RELOVA AJ, SANDLER S et al.: Effects of TNF-alpha, IFN-gamma and IL-beta on normal human bronchial epithelial cells. Eur. Respir. J. (1999) 14(1):84–91.
   PubMed Web of Science ®Google Scholar
• SULKOWSKA M, SULKOWSKI S, TERLIKOWSKI S et al.: Tumor necrosis factor-alpha induces emphysema-like pulmonary tissue rebuilding. Changes in Type II alveolar epithelial cells. Poi J. Pathol (1997) 48(3):179–188.
   Google Scholar
• VAN DEN BOSCH F, KRUITHOF E, DE VOS M et al: Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 356(9244):1821–1822.
   PubMed Web of Science ®Google Scholar
• KLIPPEL JH: Biologic therapy for rheumatoid arthritis. N Engl. I Med. (2000) 343(22):1640–1641.
   PubMed Web of Science ®Google Scholar
• BELL S, KAMM MA: Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Lancet (2000) 355(9207):858–860.
   PubMed Web of Science ®Google Scholar
• FELDMAN M, TAYLOR P, PALEOLOG E et al.: Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant. Proc. (1998) 30(8):4126–4127.
   PubMed Web of Science ®Google Scholar
• PELA R, CALCAGNI AM, SUBIACO S et al.: N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration (1999) 66(6):495–500.
   PubMed Web of Science ®Google Scholar
• KAWIKOVA I, BARNES PJ, TAKAHASHI T et al: 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am.Respic Grit. Care Med. (1996)153(2):590–596.
   PubMed Web of Science ®Google Scholar
• HORIGUCHI T, TACHIKAWA S, KONDO R et al.: Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema. Arzneimittelforschung (2002) 52(10):764–768.
   PubMed Web of Science ®Google Scholar
• ENDO S, AKIYAMA K: [Thromboxane A2 receptor antagonist in asthma therapy]. Nippon Rinsho (1996) 54(11):3045–3048.
   PubMedGoogle Scholar
• LARSSON C: Natural history and life expectancy in severe arantitrypsin deficiency, Pi Z. Acta Med. Scand. (1978) 204(5):345–351.
   PubMed Web of Science ®Google Scholar
• SEERSHOLM N, VVENCKER M, BANIK N et al.: Does al-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary al-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alphal-AT study group. Ear: Respic J. (1997) 10(10):2260–2263.
   PubMed Web of Science ®Google Scholar
• SALLENAVE JM, SHULMANN J, CROSSLEY J et al.: Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. I. Respic Cell Ma Biol. (1994) 11(6):733–741.
   PubMed Web of Science ®Google Scholar
• MCELVANEY NG, DOUJAIJI B, MOAN MJ et al: Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev Respic Dis. (1993) 148(4 Pt 1):1056–1060.
   Google Scholar
• WILLIAMS JC, FALCONE RC, KNEE C et al.: Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am. Rev Respic Dis. (1991) 144(4):875–883.
   PubMedGoogle Scholar
• OHBAYASHI H: Neutrophil elastase inhibitors as treatment for COPD. Expert Opin. Investig. Drugs (2002) 11(7):965–980.
   PubMed Web of Science ®Google Scholar
• LUISETTI M, STURANI C, SELLA D et al.: MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eui: Respic (1996) 9(7):1482–1486.
   PubMed Web of Science ®Google Scholar
• Marimastat: BB 2516, TA 2516. Drugs R D (2003) 4(3):198–203.
   PubMedGoogle Scholar
• TEIXEIRA M, GRISTWOOD RW, COOPER N et al.: Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci. (1997) 18(5):164–171.
   Google Scholar
• STURTON G, FITZGERALD M: Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest (2002) 121(5 Suppl.):192S–196S.
   Google Scholar
• COMPTON CH, GUBB J, NIEMAN R et al.: Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet (2001) 358(9278):265–270.
   PubMed Web of Science ®Google Scholar
• •Initial peer-reviewed clinical results of cilomistat. A randomised, placebo-controlled 6 week trial demonstrated an improvement in airflow and symptoms in the treatment group. zoo.
   Google Scholar
• NELL H, LEICHTL S, RATHGEB M: Acute anti-inflammatory effect of the novel phosphodiesterase inhibitor roflumilast on allergen challenge in asthmatics after a single dose [abstract]. Am. .1. Respic Grit. Care Med. (2000) 161(suppl.):A200.
   Google Scholar
• KELLERMAN DJ: P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance. Chest (2002) 121(5 Suppi.):201S-205S. zoz.
   Google Scholar
• BENNETT WD, ZEMAN KL, FOY C et al.: Effect of aerosolized uridine 5'-triphosphate on mucociliary clearance in mild chronic bronchitis. Am. .1. Respic Grit. Care Med. (2001) 164(2):302–306.
   Google Scholar
• NOONE PG, BENNETT WD, REGNIS JA et al.: Effect of aerosolized uridine-5'-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. Am. j Respic Crit. Care Med. (1999) 160(1):144–149.
   PubMed Web of Science ®Google Scholar
• BENNETT WD, OLIVIER KN, ZEMAN KL et al.: Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am. Respic Crit. Care Med. (1996) 153(6 Pt 1):1796–1801. zos. KELLERMAN DJ, BENNETT WD, ZEMAN KL: Dose response relationship of the P2Y2 agonist IN5365 of mucociliary clearance in smokers. Allergy Clin. Immunol (2001) 107:S164 [abstract]. zos. JOOS GE DE SWERT KO, PAUWELS RA: Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Ear: .1. Pharmacol (2001) 429(1–3):239–250.
   Google Scholar
• RAMNARINE SI, HIRAYAMA Y, BARNES PJ et al: 'Sensory-efferent' neural control of mucus secretion: characterization using tachykinin receptor antagonists in ferret trachea in vitro. ELI Pharmacol (1994) 113(4):1183–1190. zos. VAN SCHOOR J, JOOS GE CHASSON BL et al: The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur. Respir. (1998) 12(1):17–23. zos. JOOS G, VINCKEN W, LOUIS, RE et al: The effect of the dual NK1/NK2 tachykinin receptor antagonist DNK333A on neurokinin A-induced bronchoconstriction in patients with asthma. Am. I Respic Crit. Care Med. (2001) 1630628.
   Google Scholar
• ROGERS DF: Tachyldnin receptor antagonists for asthma and COPD. Expert Opin. Ther. Patents (2001) 11(7):1097–1121.
   Web of Science ®Google Scholar
• MCGOWAN SE: Contributions of retinoids to the generation and repair of the pulmonary alveolus. Chest (2002) 121(5 Suppi.):206S–208S.
   Google Scholar
• MASSARO GD, MASSARO D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. (1997) 3(6):675–677.
   PubMed Web of Science ®Google Scholar
• MAO JT, GOLDIN JG, DERMAND J et al.: A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am. J. Respir. Crit. Care Med. (2002) 165(5):718–723.
   PubMed Web of Science ®Google Scholar